CAGRILINTIDE

Summary

Cagrilintide is one of the most promising research peptides in the field of metabolism and weight management: it is studied for its role in satiety, energy balance, and weight reduction. Technically, it is a 37-amino acid long-acting amylin analog (NNC0174-0833 / AM833), designed as a dual agonist of amylin (AMYR) and calcitonin (CTR) receptors —DACRA class—.

Why is it being researched?

• •  Satiety control and weight reduction
• •  Gastric emptying and energy balance
• •  Peptide hormone signaling (AMYR/CTR)
• •  Metabolic homeostasis in synergy with GLP-1 agonists

Cycle & Break

Mechanism of Action

Satiety and weight control

It acts on brainstem nuclei and the hypothalamus that regulate energy balance, enhancing satiety signals and slowing gastric emptying.

AMYR/CTR and cAMP signaling

Its dual amylin/calcitonin agonism activates cAMP pathways and interactions with cellular ion transport, which is the basis of its prolonged and sustained action.

Metabolic homeostasis

Reference material for the study of peptide hormone signaling and energy homeostasis, in synergy with GLP-1 agonists.

Scientific evidence

Body weight: In phase 2 clinical trials, Cagrilintide induced weight reductions of ~10.8% in 26 weeks; combined with semaglutide (CagriSema) it achieved reductions of up to ~15-22% in subsequent studies.

DACRA profile: Receptor studies confirm its long-lasting DACRA profile.

Product use

With clinical weight reduction data among the highest in its class, Cagrilintide is a first-rate reference material in metabolic research. At Peptido BioGenetic, we offer it as a high-purity peptide, with a Certificate of Analysis (COA) available upon request.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.